Regulus Therapeutics Inc. (RGLS)
| Previous Close | 2.2300 |
| Open | 2.2000 |
| Bid | 2.2600 x 100 |
| Ask | 2.3000 x 100 |
| Day's Range | 2.1600 - 2.3200 |
| 52 Week Range | 1.0800 - 3.7900 |
| Volume | |
| Avg. Volume | 3,228,447 |
| Market Cap | 148.606M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5800 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.20 |
PR NewswireRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three
- PR Newswire
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.
- GuruFocus.com
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
